Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics

Highlights • Hyperprolactinemia is an underappreciated adverse-effects of antipsychotics (APS). • Hyperprolactinemia consequences compromise treatment adherence and can be serious. • We recommend routine determination of the prolactin levels of patients receiving APS. • Treatment strategies include...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Frontiers in neuroendocrinology 2017-04, Vol.45, p.25-34
Hauptverfasser:	Montejo, Ángel L, Arango, Celso, Bernardo, Miquel, Carrasco, José L, Crespo-Facorro, Benidicto, Cruz, Juan J, Del Pino-Montes, Javier, García-Escudero, Miguel A, García-Rizo, Clemente, González-Pinto, Ana, Hernández, Ana I, Martín-Carrasco, Manuel, Mayoral-Cleries, Fermín, Mayoral-van Son, Jaqueline, Mories, M. Teresa, Pachiarotti, Isabella, Pérez, Jesús, Ros, Salvador, Vieta, Eduard
Format:	Artikel
Sprache:	eng
Schlagworte:	Antipsychotic Agents - therapeutic use Aripiprazole - therapeutic use Consensus Endocrinology & Metabolism Humans Hyperprolactinemia - drug therapy Iatrogenic Disease - prevention & control Mental Disorders - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Hyperprolactinemia is an underappreciated adverse-effects of antipsychotics (APS). • Hyperprolactinemia consequences compromise treatment adherence and can be serious. • We recommend routine determination of the prolactin levels of patients receiving APS. • Treatment strategies include dose reduction, switching APS, or adding an antidote.
ISSN:	0091-3022 1095-6808
DOI:	10.1016/j.yfrne.2017.02.003